查看購物車
  • English
  • Japanese
梅毒市場－全球及區域分析：依治療方法、給藥途徑及地區分類－分析與預測（2026-2036 年）
市場調查報告書
商品編碼
2015255

梅毒市場－全球及區域分析：依治療方法、給藥途徑及地區分類－分析與預測（2026-2036 年）

Syphilis Market - A Global and Regional Analysis: Treatment Type, Route of Administration, and Regional Analysis - Analysis and Forecast, 2026-2036
出版日期: | 出版商: BIS Research | 英文 109 Pages | 商品交期: 1-5個工作天內

價格

2024 年全球梅毒市場價值為 7.18 億美元，但預計到 2036 年將達到 12.208 億美元，2026 年至 2036 年的複合年成長率高達 4.60%。

關鍵市場統計數據
預測期 2026-2036
2026 年市場規模 7.783億美元
2036年的預測 12.208億美元
複合年成長率 4.6%

性行為感染感染率上升、早期診斷和治療意識增強以及已開發國家和開發中國家篩檢計畫擴展等因素的推動，全球梅毒市場正經歷顯著成長。公共衛生工作的加強、診斷檢測可及性的改善以及為控制梅毒傳播而採取的醫療保健措施的改進，都促進了市場擴張。

此外，診斷技術的進步，包括快速且更準確的臨床檢測，提高了梅毒的檢出率，並實現了及時的臨床干預。對孕產婦和產前篩檢的日益重視，以及對感染疾病控制和性健康計畫的投入增加，也對市場產生了正面影響。隨著對有效診斷、治療和預防策略的需求持續成長，預計全球梅毒市場將在預測期內保持穩定成長。

市場概覽

全球梅毒市場正穩步成長，預計未來將繼續擴張，這主要得益於公眾意識的提高、診斷方法的進步以及公共衛生部門為遏制性行為感染（STI）蔓延而採取的措施。市場成長的主要促進因素是梅毒盛行率的上升，尤其是在高風險族群中，以及人們越來越重視早期診斷和治療，以遏制感染的傳播並預防併發症，包括先天性梅毒。診斷檢測的普及，包括快速就地檢驗和更先進的臨床檢測，在推動市場擴張方面發揮重要作用。此外，政府主導的旨在意識提升的各項措施和醫療保健計劃的增加，以及對更有效治療方法日益成長的需求，都進一步推動了市場的成長。

對產業的影響

受對更先進的診斷方法、治療方法和預防措施的需求不斷成長的推動，全球梅毒市場正經歷顯著成長。這種成長對包括醫療保健、製藥和公共衛生在內的多個行業產生了重大影響。在醫療產業，梅毒病例的增加促使人們更加重視早期發現和有效管理，從而加速了快速檢測套組等先進診斷工具和改進的臨床實驗室方法的應用。

在製藥領域，人們對開發治療梅毒的新治療方法和新選擇，以及治療常伴隨梅毒發生的合併感染疾病的藥物越來越感興趣。這刺激了研發領域的創新和投資，從而促進了製藥業的成長。

公共衛生領域也受到了顯著影響，各國政府和非政府組織（NGO）正加強透過宣傳宣傳活動、疫苗接種計劃和產前篩檢來預防先天性梅毒，從而遏制梅毒的蔓延。這些努力推動了對更便利的檢測和治療方法的需求成長，重塑了市場動態，並促進了該行業的進一步發展。

這些領域之間的協同作用正在推動對梅毒採取更強力、更全面的應對措施，最終改善全球健康狀況，並推動市場持續成長。

市場區隔:

細分 1：依給藥途徑

  • 注射藥物
  • 口服藥物

在梅毒市場（按給藥途徑分類），注射劑藥物預計將佔據主導地位。

就給藥途徑而言，注射劑預計將主導梅毒市場。這是因為注射用抗生素，特別是青黴素，在治療梅毒感染疾病已被證實有效。青黴素仍然是梅毒的標準治療方法，尤其是在晚期梅毒（如第三期梅毒和先天性梅毒）。注射用青黴素因其生物利用度高，且能快速可靠地發揮治療作用而備受青睞。

在臨床實務中，注射以青黴素特別受歡迎，因為它能確保劑量穩定可控，這對於有效治療梅毒和預防併發症至關重要。肌注青黴素（通常為芐星青黴素G）是治療方法不同階段梅毒的建議方法。這種給藥途徑能使抗生素在體內維持較長時間的活性，有助於清除引起梅毒的梅毒螺旋體。

鑑於注射用抗生素仍然是標準治療方法，而且全球梅毒病例數量不斷增加，在既定的臨床指南和注射用抗生素的有效性的支持下，注射用抗生素領域預計將保持其市場主導地位。

分割方式 2：依治療方法

  • 青黴素類藥物治療
  • 其他抗生素

預計青黴素類藥物將成為梅毒治療市場的主導療法（按治療方法）。

青黴素已被證實對治療感染疾病有效，並且仍然是梅毒治療的黃金標準；因此，基於青黴素的治療方法預計將主導梅毒市場。青黴素，特別是芐星青黴素G，廣泛用於治療各階段的梅毒，從早期和二期到潛伏期和第三期。它對致病菌梅毒螺旋體（Treponema pallidum）具有極高的療效，幾十年來一直是梅毒治療的基礎，因此被推薦為第一線藥物。

青黴素的優越性得到了長期臨床成功以及包括世界衛生組織（WHO）和美國疾病管制與預防中心（CDC）在內的國際衛生組織制定的指南的支持。這些組織推薦青黴素作為梅毒的第一線治療藥物。注射用青黴素可在體內長期停留，為治療梅毒提供了可靠的單劑量解決方案。

由於青黴素類治療方法易於取得、價格實惠且具有強大的臨床證據，因此它仍將是治療梅毒最常用和首選的藥物，並且在可預見的未來很可能繼續保持其在市場上的主導地位。

細分3：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 北美洲，美國
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞洲及大洋洲
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 亞洲和大洋洲的其他地區
  • 其他地區
    • 拉丁美洲和加勒比海地區
    • 北非和中東

區域腦膜炎球菌市場：預計亞洲和大洋洲將佔據主導地位

由於性行為感染​​感染（STI）發病率上升、公眾意識增強以及醫療基礎設施改善，亞太地區預計將成為梅毒市場的主要驅動力。這兩個地區人口密度高，醫療服務覆蓋範圍廣，因此都在加強公共衛生力度，透過早期診斷、治療和預防計畫來對抗梅毒。

在亞洲，由於都市化、性行為改變以及性健康意識增強等因素，中國、印度和日本等國的梅毒病例正在增加。這些國家正透過政府計畫、篩檢計畫和宣傳宣傳活動，加強預防性性行為感染感染（STI），促進了市場成長。醫療服務的擴展，尤其是在遍遠地區，進一步推動了對診斷檢測和治療的需求。

在大洋洲，特別是澳洲和紐西蘭，公共衛生部門正強調梅毒篩檢的重要性，尤其要重視孕婦的篩檢，以預防先天性梅毒。此外，完善的醫療保健體係以及性健康意識的提高，正在擴大梅毒檢測和治療的覆蓋範圍。

隨著人們對梅毒的認知不斷提高，以及這些地區醫療保健服務的改善，預計亞洲和大洋洲將繼續保持其在全球梅毒市場的主導地位，這主要得益於對有效診斷和治療方法的需求不斷成長。

梅毒市場近期趨勢

  • 截至 2026 年 2 月，Aurobindo Pharma Limited 預計透過擴大其位於安得拉邦的綜合工廠的產能，將在 12 個月內實現青黴素 G (Pen-G) 約 10,000 公噸的產量。
  • 2026 年 1 月，印度對青黴素及其主要衍生物（青黴素 G、6-氨基青黴素和三水阿莫西林）實施了為期一年的最低進口價格 (MIP)，以遏制低價進口，特別是來自中國的進口，並保護像 Aurobindo Pharma Limited 這樣的國內製造商。
  • 2025 年 3 月，山德士集團股份公司在奧地利昆德爾開設了一家新的抗生素生產廠，耗資 5,000 萬歐元，使產量提高了約 20%（每年 2.4 億包），並能夠額外生產 10 億片青黴素片，以滿足不斷成長的全球需求。

需求——促進因素、挑戰與機遇

市場促進因素

梅毒發病率上升：全球梅毒的捲土重來反映出預防、早期發現和持續公共衛生投入方面的系統性缺陷，即使在高所得國家也是如此。男男性行為者（MSM）、免疫力缺乏病毒感染者和孕婦受到的影響尤其嚴重，這表明結構性和行為性脆弱性依然存在；而先天性病例的增加則表明孕產婦篩檢和治療項目存在重大缺陷。保險套使用率下降、網路性行為增加、社會歧視以及醫療保健服務取得的不平等現象表明，目前的措施不足以應對疫情。如果沒有針對特定族群的綜合干預措施和加強監測系統，那麼到2035年梅毒發病率將持續居高不下的預測很可能成為現實。

市場挑戰

芐星青黴素G（梅毒一線治療金標準）的反覆供不應求嚴重限制了市場成長。間歇性的供應供不應求、生產集中以及低利潤率的經濟結構限制了該藥物的穩定供應，尤其對孕婦等高危險群而言更是如此。這種不穩定性迫使人們依賴臨床療效有限的替代療法，降低了治療指引的依從性，並影響了整體治療量。此外，採購的不確定性和訂單積壓也削弱了生產商和公共衛生項目的收入可預測性。如果沒有供應鏈多元化和生產獎勵，芐星青黴素G的供不應求將繼續成為梅毒市場的結構性限制。

市場機遇

梅毒診斷檢測的普及與推廣—在快速、即時檢測 (POC)、居家檢測和自動化檢測解決方案創新推動下，梅毒市場正經歷強勁成長。獲得 FDA已通過核准的即時檢測和非處方檢測產品，例如梅毒健康檢查 (Syphilis Health Check) 和“First to Know Syphilis Test”，正在擴大檢測範圍，減少社會歧視，並實現當日啟動治療。 HIV-梅毒聯合檢測和自動化梅毒螺旋體免疫檢測正在簡化高流量、高風險環境下的工作流程，提高效率和診斷準確性。公共衛生舉措、複檢通訊協定以及與更廣泛的性行為感染(STI)篩檢計畫的整合進一步推動了市場擴張。分析師認為，這些趨勢將形成永續的成長軌跡，分散式檢查檢測和檢查室檢測都將推動長期市場滲透和商機。

這份報告將為貴組織帶來哪些價值？

產品與創新策略－全球梅毒市場細分為多個關鍵部分，包括給藥途徑、治療方法和區域市場。透過了解哪些細分市場佔據最大的市場佔有率以及哪些細分市場具有成長潛力，本報告為旨在創新產品和擴展產品組合的企業提供了寶貴的見解。

成長和行銷策略—策略夥伴關係、聯盟和業務擴張預計將在梅毒市場的成長中發揮核心作用。

競爭策略：梅毒市場競爭異常激烈，許多老字型大小企業提供各種診斷方案和青黴素類藥物療法。製藥公司致力於提供有效的治療方法，而診斷公司則致力於開發更快、更準確的檢測方法。公共衛生組織也透過宣傳宣傳活動和篩檢計畫做出貢獻。隨著對更精準診斷和治療的需求不斷成長，市場參與者正致力於提升服務水準並擴大業務範圍，以保持競爭力。

調查方法

市場設計與檢驗的關鍵考量與假設

  • 為了估算全球市場規模，涵蓋的期間為 2024 年至 2036 年，其中 2024 年為基準年，2026 年至 2036 年為預測期。
  • 本報告的研究範圍是基於來自醫療保健、製藥、診斷、公共衛生和監管機構等行業專家的見解。報告對梅毒市場進行了詳細分析，涵蓋趨勢、成長要素、競爭格局和新興機遇，同時檢驗了診斷和治療方法的進步等因素。
  • 預計梅毒市場未來將出現顯著成長，這項預測是基於對現有解決方案的歷史數據分析得出的。
  • 每家公司的企業獲利均根據其2024年年度報告計算。對於私人公司，企業獲利估算則來自一手調查數據、資金籌措歷史、市場合作關係和業務表現。
  • 本報告基於現有的梅毒相關產品和服務，對市場進行了分析。報告識別並概述了該領域提供重要產品和服務的主要企業。

主要市場參與者和競爭格局概述

本報告中介紹的公司簡介是根據對每家公司的業務範圍、產品系列和市場滲透率的分析而選擇的。

該市場的主要企業包括以下幾家：

  • AdvaCare Pharma
  • Centurion Healthcare
  • Cipla
  • Eurofarma
  • Fresenius Kabi AG
  • Jolly Healthcare
  • Laboratoires Delbert
  • Pfizer Inc.
  • Sandoz Group AG
  • Teva Pharmaceuticals

目錄

執行摘要

第1章：全球梅毒市場：產業展望

  • 市場概覽
    • 市場概覽
  • 流行病學分析
  • 市場趨勢
    • 影響分析
  • 監理情勢
    • 美國法規結構
    • 歐洲的法規結構
    • 亞洲和大洋洲的法規結構
  • 管道分析
  • 市場動態
    • 促進因素、挑戰和機會：當前和未來影響評估
    • 市場促進因素
    • 市場挑戰
    • 市場機遇

第2章：全球梅毒市場（依治療方法分類），百萬美元，2024-2036年

  • 青黴素類藥物治療
  • 其他抗生素

第3章：全球梅毒市場（依給藥途徑分類），百萬美元，2024-2036年

  • 注射藥物
  • 口服藥物

第4章：全球梅毒市場（按地區分類），百萬美元，2024-2036年

  • 區域概況
  • 北美洲
  • 歐洲
  • 亞洲及大洋洲
  • 其他地區

第5章：競爭標竿分析與公司概況

  • 關鍵策略與趨勢（2021年1月至2026年2月）
  • 主要發展分析（依公司分類）
  • 公司簡介
    • AdvaCare Pharma
    • Centurion Healthcare
    • Cipla
    • Eurofarma
    • Fresenius Kabi AG
    • Jolly Healthcare
    • Laboratoires Delbert
    • Pfizer Inc.
    • Sandoz Group AG
    • Teva Pharmaceuticals

第6章：調查方法

Product Code: BHL3100SA

This report can be delivered within 1 working day.

Introduction of the Syphilis Market

The global syphilis market, initially valued at $718.0 million in 2024, is projected to grow substantially, reaching $1,220.8 million by 2036, reflecting a remarkable compound annual growth rate (CAGR) of 4.60% from 2026 to 2036.

KEY MARKET STATISTICS
Forecast Period2026 - 2036
2026 Evaluation$778.3 Million
2036 Forecast$1,220.8 Million
CAGR4.6%

The global syphilis market is experiencing significant growth, driven by the rising incidence of sexually transmitted infections, increasing awareness regarding early diagnosis and treatment, and the expanding availability of screening programs across both developed and developing regions. Growing public health initiatives, improved access to diagnostic testing, and stronger efforts by healthcare organizations to control the spread of syphilis are contributing to market expansion.

In addition, advancements in diagnostic technologies, including rapid testing methods and more accurate laboratory-based assays, are improving detection rates and supporting timely clinical intervention. The market is also benefiting from greater emphasis on maternal and prenatal screening to prevent congenital syphilis, alongside increasing investments in infectious disease management and sexual health programs. As demand for effective diagnosis, treatment, and prevention strategies continues to rise, the global syphilis market is expected to maintain steady growth over the forecast period.

Market Introduction

The global syphilis market has experienced steady growth and is projected to continue expanding, driven by increasing awareness, advancements in diagnostic methods, and growing public health efforts to control the spread of sexually transmitted infections (STIs). The market growth is primarily fuelled by rising syphilis incidence rates, particularly in high-risk populations, and an increasing focus on early diagnosis and treatment to reduce transmission and prevent complications, including congenital syphilis. Enhanced access to diagnostic tests, including rapid point-of-care tests and improved laboratory diagnostics, is playing a key role in driving market expansion. Additionally, the rise of government initiatives and healthcare programs aimed at improving sexual health awareness, alongside the growing demand for more effective treatment options, further supports the market's growth trajectory.

Industrial Impact

The global syphilis market has witnessed significant growth, driven by the increasing demand for improved diagnostics, treatments, and preventive measures. This growth is having a substantial impact across various industries, including healthcare, pharmaceuticals, and public health. In the healthcare industry, the rise in syphilis cases has led to greater emphasis on early detection and effective management, encouraging the adoption of advanced diagnostic tools like rapid testing kits and improved laboratory assays.

In the pharmaceutical sector, there has been a growing focus on developing new treatments and therapeutic options for syphilis, as well as medications to address co-infections often associated with the disease. This has spurred innovation and investment in research and development, contributing to the growth of the pharmaceutical industry.

The public health sector is also significantly impacted, with governments and non-governmental organizations ramping up efforts to combat syphilis through awareness campaigns, vaccination programs, and prenatal screenings to prevent congenital syphilis. These efforts are increasing demand for more accessible testing and treatment options, thus shaping the market dynamics and driving further industry advancements.

The synergy between these sectors is fostering a more robust and integrated response to syphilis, ultimately enhancing global health outcomes while driving continued growth in the market.

Market Segmentation:

Segmentation 1: By Route of Administration

  • Injectables
  • Oral Medications

Injectables Segment to Dominate the Syphilis Market (by Route of Administration)

The injectables segment is expected to dominate the syphilis market by route of administration, driven by the proven efficacy of injectable antibiotics, particularly penicillin, in treating syphilis infections. Penicillin remains the standard treatment for syphilis, especially in its later stages, such as tertiary syphilis or congenital syphilis. The injectable form of penicillin is preferred due to its high bioavailability and ability to provide a rapid and reliable therapeutic effect.

Injectables are particularly favoured in clinical settings due to their ability to ensure consistent and controlled dosing, which is essential for effectively treating syphilis and preventing complications. The intramuscular (IM) administration of penicillin, commonly in the form of Benzathine penicillin G, is the recommended treatment for syphilis across various stages of infection. This method of administration ensures that the antibiotic remains active in the body for a prolonged period, helping to eliminate the syphilis-causing bacterium, Treponema pallidum.

As the standard treatment remains an injectable, and due to the growing number of syphilis cases globally, the injectables segment is anticipated to continue its dominance in the market, supported by the established clinical guidelines and the proven effectiveness of injectable antibiotics.

Segmentation 2: By Treatment Type

  • Penicillin-based Treatment
  • Other Antibiotics

Penicillin-based Treatment to Dominate the Syphilis Market (by Treatment Type)

Penicillin-based treatment is expected to dominate the syphilis market by treatment type, as penicillin remains the gold standard for syphilis therapy due to its proven effectiveness in curing the infection. Penicillin, particularly Benzathine penicillin G, is widely used to treat syphilis at all stages, from primary and secondary to latent and tertiary syphilis. It is the preferred treatment because it is highly effective against the causative bacterium, Treponema pallidum, and has been the cornerstone of syphilis management for decades.

Penicillin's dominance is supported by its long history of clinical success and established guidelines from global health organizations, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), which recommend it as the first-line treatment for syphilis. The injectable form of penicillin ensures that the drug remains in the system for a prolonged period, offering a reliable, single-dose solution for treating syphilis.

Due to its widespread availability, affordability, and strong clinical evidence, penicillin-based treatments will continue to be the most prescribed and preferred option for syphilis treatment, maintaining their dominant position in the market for the foreseeable future.

Segmentation 3: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia and Oceania
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest-of-Asia and Oceania
  • Rest-of-the-World
    • Latin America and Caribbean
    • North Africa and Middle East

Asia and Oceania to Dominate the Syphilis Market (by Region)

Asia and Oceania are expected to dominate the syphilis market due to the rising incidence of sexually transmitted infections (STIs), increasing awareness, and improving healthcare infrastructure in the region. With high population densities and expanding access to healthcare, both regions are experiencing significant public health efforts to combat syphilis through early diagnosis, treatment, and prevention programs.

In Asia, countries such as China, India, and Japan are witnessing an uptick in syphilis cases, driven by factors such as urbanization, changing sexual behaviors, and a growing focus on sexual health. These countries are also increasing their efforts in STI prevention through government programs, screening initiatives, and awareness campaigns, which are contributing to market growth. The expansion of healthcare services, especially in rural areas, is further driving demand for diagnostic tests and treatments.

In Oceania, particularly in Australia and New Zealand, public health authorities are emphasizing the importance of syphilis screening, particularly for pregnant women, to prevent congenital syphilis. Additionally, the implementation of robust healthcare systems, along with a growing focus on sexual health, is promoting syphilis testing and treatment availability.

As awareness and healthcare access continue to improve in these regions, Asia and Oceania are set to maintain a dominant position in the global syphilis market, driven by increased demand for effective diagnosis and treatment options.

Recent Developments in the Syphilis Market

  • As of February 2026, Aurobindo Pharma Limited expects Penicillin-G (Pen-G) production to reach ~10,000 metric tonnes within 12 months as it scales output from its integrated Andhra Pradesh facility.
  • In January 2026, India imposed a one-year minimum import price (MIP) on penicillin and key derivatives (Pen-G, 6-APA, amoxicillin trihydrate) to curb low-cost imports, especially from China, and protect domestic manufacturers such as Aurobindo Pharma Limited.
  • In March 2025, Sandoz Group AG opened a new €50 million antibiotic production facility in Kundl, Austria, boosting output by ~20% (to 240 million packages/year) and enabling production of one billion additional penicillin tablets to meet rising global demand.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Rising Incidence of Syphilis: The global resurgence of syphilis reflects systemic gaps in prevention, early detection, and sustained public health investment, even in high-income settings. Disproportionate impacts among MSM, people living with human immunodeficiency virus (HIV), and pregnant women indicate persistent structural and behavioural vulnerabilities, while rising congenital cases signal critical failures in maternal screening and treatment programs. The convergence of reduced condom use, digital sexual networking, stigma, and uneven healthcare access suggests that current control strategies are insufficiently adaptive. Without integrated, population-specific interventions and strengthened surveillance, projections of sustained high incidence through 2035 are likely to materialize.

Market Challenges

Recurrent Shortage of the Primary Treatment, Benzathine Penicillin G: The recurrent shortage of benzathine penicillin G (BPG), the gold-standard first-line therapy for syphilis, is significantly constraining market growth. Persistent supply disruptions, manufacturing concentration, and low-margin economics limit consistent drug availability, particularly for high-risk groups such as pregnant women. This instability forces reliance on alternative regimens with clinical limitations, reducing adherence to treatment guidelines and affecting overall treatment volumes. Additionally, procurement uncertainty and backorders weaken revenue predictability for manufacturers and public health programs. Without supply chain diversification and production incentives, BPG shortages will continue to act as a structural restraint on the syphilis market.

Market Opportunities

Expansion of Advanced and Accessible Syphilis Diagnostic Testing: The syphilis market is experiencing robust growth driven by innovations in rapid, point-of-care, at-home, and automated testing solutions. FDA-cleared POC and OTC tests, such as the Syphilis Health Check and First to Know Syphilis Test, are expanding access, reducing stigma, and enabling same-day treatment initiation. Dual HIV-syphilis assays and automated treponemal immunoassays are streamlining workflows in high-volume and high-risk settings, improving efficiency and diagnostic accuracy. Market expansion is further supported by public health initiatives, repeat testing protocols, and integration into broader STI screening programs. Analysts view these trends as creating a sustainable growth trajectory, with both decentralized and lab-based testing driving long-term adoption and revenue opportunities.

How can this report add value to an organization?

Product/Innovation Strategy: The global syphilis market has been divided into several key segments, including route of administration, treatment type, and regional markets. By understanding which segments hold the largest share and which ones show potential for growth, this report offers invaluable insights for organizations looking to innovate and expand their product offerings.

Growth/Marketing Strategy: Strategic partnerships, collaborations, and business expansions are anticipated to be central to the growth of the syphilis market.

Competitive Strategy: The syphilis market is highly competitive, with numerous well-established players offering a range of diagnostic solutions and penicillin-based treatments. Pharmaceutical companies focus on providing effective therapies, while diagnostic firms are innovating with faster, more accurate testing methods. Public health organizations also contribute through awareness campaigns and screening programs. As demand for better diagnosis and treatment increases, market players are focusing on enhancing their offerings and expanding their reach to stay competitive.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2024 to 2036 have been considered for the global market size estimation, 2024 has been considered as the base year, and 2026 to 2036 as the forecast period.
  • The scope of the report is based on insights from industry experts across healthcare, pharmaceuticals, diagnostics, public health, and regulatory bodies. It offers a detailed analysis of the syphilis market, covering trends, growth drivers, competition, and emerging opportunities, while examining factors like advancements in diagnostics and treatment options.
  • The market for syphilis is anticipated to grow substantially in the future, with projections based on historical analysis of available solutions.
  • Revenues from companies have been sourced from their annual reports for FY2024. For private companies, revenue estimates are derived from primary research inputs, funding history, market collaborations, and operational performance.
  • The market has been mapped based on the existing syphilis products and services. Key companies with significant offerings in this field have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts in syphilis, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of report segmentations and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investors' presentations of the leading market players
  • Company websites and a detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players in the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • AdvaCare Pharma
  • Centurion Healthcare
  • Cipla
  • Eurofarma
  • Fresenius Kabi AG
  • Jolly Healthcare
  • Laboratoires Delbert
  • Pfizer Inc.
  • Sandoz Group AG
  • Teva Pharmaceuticals

Table of Contents

Executive Summary

Scope and Definition

1 Global Syphilis Market: Industry Outlook

  • 1.1 Market Overview
    • 1.1.1 Market Overview
  • 1.2 Epidemiological Analysis
  • 1.3 Market Trends
    • 1.3.1 Impact Analysis
      • 1.3.1.1 Integrated Antenatal Infection Panels (HIV-HBV-Syphilis) Becoming a Standard Procurement and Scale-Up Model
      • 1.3.1.2 Self-Testing and Decentralized Testing Expanding the Addressable Treatment Population
  • 1.4 Regulatory Landscape
    • 1.4.1 Regulatory Framework in the U.S.
    • 1.4.2 Regulatory Framework in Europe
    • 1.4.3 Regulatory Framework in Asia and Oceania
      • 1.4.3.1 Regulatory Framework in China
      • 1.4.3.2 Regulatory Framework in Japan
      • 1.4.3.3 Regulatory Framework in Australia
  • 1.5 Pipeline Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
    • 1.6.2 Market Drivers
      • 1.6.2.1 Rising Incidence of Syphilis
      • 1.6.2.2 Increased Screening Initiatives
    • 1.6.3 Market Challenges
      • 1.6.3.1 Recurrent Shortage of the Primary Treatment, Benzathine Penicillin G
      • 1.6.3.2 Limited Availability of Alternative Therapies for Syphilis
    • 1.6.4 Market Opportunities
      • 1.6.4.1 Expansion of Advanced and Accessible Syphilis Diagnostic Testing

2 Global Syphilis Market (by Treatment Type), $Million, 2024-2036

  • 2.1 Penicillin-based Treatment
    • 2.1.1 Overview
    • 2.1.2 Market Sizing and Forecast
  • 2.2 Other Antibiotics
    • 2.2.1 Overview
    • 2.2.2 Market Sizing and Forecast

3 Global Syphilis Market (by Route of Administration), $Million, 2024-2036

  • 3.1 Injectables
    • 3.1.1 Overview
    • 3.1.2 Market Sizing and Forecast
  • 3.2 Oral Medications
    • 3.2.1 Overview
    • 3.2.2 Market Sizing and Forecast

4 Global Syphilis Market (by Region), $Million, 2024-2036

  • 4.1 Regional Summary
  • 4.2 North America
    • 4.2.1 Regional Overview
    • 4.2.2 Driving Factors for Market Growth
    • 4.2.3 Factors Challenging the Market
    • 4.2.4 Analyst View
    • 4.2.5 Market Sizing and Forecast
      • 4.2.5.1 North America Syphilis Market, by Country
        • 4.2.5.1.1 U.S.
        • 4.2.5.1.2 Canada
  • 4.3 Europe
    • 4.3.1 Regional Overview
    • 4.3.2 Driving Factors for Market Growth
    • 4.3.3 Factors Challenging the Market
    • 4.3.4 Analyst View
    • 4.3.5 Market Sizing and Forecast
      • 4.3.5.1 Europe Syphilis Market, by Country
        • 4.3.5.1.1 U.K.
        • 4.3.5.1.2 Germany
        • 4.3.5.1.3 France
        • 4.3.5.1.4 Italy
        • 4.3.5.1.5 Spain
        • 4.3.5.1.6 Rest-of-Europe
  • 4.4 Asia and Oceania
    • 4.4.1 Regional Overview
    • 4.4.2 Driving Factors for Market Growth
    • 4.4.3 Factors Challenging the Market
    • 4.4.4 Analyst View
    • 4.4.5 Market Sizing and Forecast
      • 4.4.5.1 Asia and Oceania Syphilis Market, by Country
        • 4.4.5.1.1 China
        • 4.4.5.1.2 Japan
        • 4.4.5.1.3 India
        • 4.4.5.1.4 South Korea
        • 4.4.5.1.5 Australia
        • 4.4.5.1.6 Rest-of-Asia and Oceania
  • 4.5 Rest-of-the-World
    • 4.5.1 Regional Overview
    • 4.5.2 Driving Factors for Market Growth
    • 4.5.3 Factors Challenging the Market
    • 4.5.4 Analyst View
    • 4.5.5 Market Sizing and Forecast
      • 4.5.5.1 Rest-of-the-World Syphilis Market, by Country
        • 4.5.5.1.1 Latin America and Caribbean
        • 4.5.5.1.2 North Africa and Middle East

5 Competitive Benchmarking and Company Profiles

  • 5.1 Key Strategies and Developments, January 2021-February 2026
  • 5.2 Key Developments Analysis (by Company)
  • 5.3 Company Profiles
    • 5.3.1 AdvaCare Pharma
      • 5.3.1.1 Overview
      • 5.3.1.2 Top Products/Product Portfolio
      • 5.3.1.3 Top Competitors
      • 5.3.1.4 Target Customers
      • 5.3.1.5 Key Personnel
      • 5.3.1.6 Analyst View
    • 5.3.2 Centurion Healthcare
      • 5.3.2.1 Overview
      • 5.3.2.2 Top Products/Product Portfolio
      • 5.3.2.3 Top Competitors
      • 5.3.2.4 Target Customers
      • 5.3.2.5 Key Personnel
      • 5.3.2.6 Analyst View
    • 5.3.3 Cipla
      • 5.3.3.1 Overview
      • 5.3.3.2 Top Products/Product Portfolio
      • 5.3.3.3 Top Competitors
      • 5.3.3.4 Target Customers
      • 5.3.3.5 Key Personnel
      • 5.3.3.6 Analyst View
    • 5.3.4 Eurofarma
      • 5.3.4.1 Overview
      • 5.3.4.2 Top Products/Product Portfolio
      • 5.3.4.3 Top Competitors
      • 5.3.4.4 Target Customers
      • 5.3.4.5 Key Personnel
      • 5.3.4.6 Analyst View
    • 5.3.5 Fresenius Kabi AG
      • 5.3.5.1 Overview
      • 5.3.5.2 Top Products/Product Portfolio
      • 5.3.5.3 Top Competitors
      • 5.3.5.4 Target Customers
      • 5.3.5.5 Key Personnel
      • 5.3.5.6 Analyst View
    • 5.3.6 Jolly Healthcare
      • 5.3.6.1 Overview
      • 5.3.6.2 Top Products/Product Portfolio
      • 5.3.6.3 Top Competitors
      • 5.3.6.4 Target Customers
      • 5.3.6.5 Key Personnel
      • 5.3.6.6 Analyst View
    • 5.3.7 Laboratoires Delbert
      • 5.3.7.1 Overview
      • 5.3.7.2 Top Products/Product Portfolio
      • 5.3.7.3 Top Competitors
      • 5.3.7.4 Target Customers
      • 5.3.7.5 Key Personnel
      • 5.3.7.6 Analyst View
    • 5.3.8 Pfizer Inc.
      • 5.3.8.1 Overview
      • 5.3.8.2 Top Products/Product Portfolio
      • 5.3.8.3 Top Competitors
      • 5.3.8.4 Target Customers
      • 5.3.8.5 Key Personnel
      • 5.3.8.6 Analyst View
    • 5.3.9 Sandoz Group AG
      • 5.3.9.1 Overview
      • 5.3.9.2 Top Products/Product Portfolio
      • 5.3.9.3 Top Competitors
      • 5.3.9.4 Target Customers
      • 5.3.9.5 Key Personnel
      • 5.3.9.6 Analyst View
    • 5.3.10 Teva Pharmaceuticals
      • 5.3.10.1 Overview
      • 5.3.10.2 Top Products/Product Portfolio
      • 5.3.10.3 Top Competitors
      • 5.3.10.4 Target Customers
      • 5.3.10.5 Key Personnel
      • 5.3.10.6 Analyst View

6 Research Methodology

  • 6.1 Data Sources
    • 6.1.1 Primary Data Sources
    • 6.1.2 Secondary Data Sources
    • 6.1.3 Data Triangulation
  • 6.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Syphilis Market (by Scenario), $Million, 2024, 2026, and 2036
  • Figure 2: Global Syphilis Market, 2024 and 2036
  • Figure 3: Global Syphilis Market (by Country), $Million, 2024
  • Figure 4: Global Syphilis Market, $Million, 2024 and 2036
  • Figure 5: Global Syphilis Market (by Treatment Type), $Million, 2024, 2029, and 2036
  • Figure 6: Global Syphilis Market (by Route of Administration), $Million, 2024, 2029, and 2036
  • Figure 7: Global Syphilis Market (by Treatment Type), $Million, 2025, 2030, and 2036
  • Figure 8: Global Syphilis Market (Penicillin-based Treatment), $Million, 2024-2036
  • Figure 9: Global Syphilis Market (Other Antibiotics), $Million, 2024-2036
  • Figure 10: Global Syphilis Market (by Route of Administration), $Million, 2025, 2030, and 2036
  • Figure 11: Global Syphilis Market (Injectables), $Million, 2024-2036
  • Figure 12: Global Syphilis Market (Oral Medications), $Million, 2024-2036
  • Figure 13: North America Syphilis Market, $Million, 2024-2036
  • Figure 14: U.S. Syphilis Market, $Million, 2024-2036
  • Figure 15: Canada Syphilis Market, $Million, 2024-2036
  • Figure 16: Europe Syphilis Market, $Million, 2024-2036
  • Figure 17: U.K. Syphilis Market, $Million, 2024-2036
  • Figure 18: Germany Syphilis Market, $Million, 2024-2036
  • Figure 19: France Syphilis Market, $Million, 2024-2036
  • Figure 20: Italy Syphilis Market, $Million, 2024-2036
  • Figure 21: Spain Syphilis Market, $Million, 2024-2036
  • Figure 22: Rest-of-Europe Syphilis Market, $Million, 2024-2036
  • Figure 23: Asia and Oceania Syphilis Market, $Million, 2024-2036
  • Figure 24: China Syphilis Market, $Million, 2024-2036
  • Figure 25: Japan Syphilis Market, $Million, 2024-2036
  • Figure 26: India Syphilis Market, $Million, 2024-2036
  • Figure 27: South Korea Syphilis Market, $Million, 2024-2036
  • Figure 28: Australia Syphilis Market, $Million, 2024-2036
  • Figure 29: Rest-of-Asia and Oceania Syphilis Market, $Million, 2024-2036
  • Figure 30: Rest-of-the-World Syphilis Market, $Million, 2024-2036
  • Figure 31: Latin America and Caribbean Syphilis Market, $Million, 2024-2036
  • Figure 32: North Africa and Middle East Syphilis Market, $Million, 2024-2036
  • Figure 33: Key Strategies and Developments, January 2021-February 2026
  • Figure 34: Data Triangulation
  • Figure 35: Top-Down and Bottom-Up Approach
  • Figure 36: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Epidemiological Analysis of Incidence of Syphilis, 2019-2023
  • Table 3: Pipeline Analysis
  • Table 4: Global Syphilis Market (by Region), $Million, 2024-2036
  • Table 5: North America Syphilis Market (by Country), $Million, 2024-2036
  • Table 6: Europe Syphilis Market (by Country), $Million, 2024-2036
  • Table 7: Asia and Oceania Syphilis Market (by Country), $Million, 2024-2036
  • Table 8: Rest-of-the-World Syphilis Market (by Country), $Million, 2024-2036
  • Table 9: Major Key Strategies, January 2021-February 2026